Prosecution Insights
Prosecution Insights
18 pending office actions • 14 clients • 18 examiners • 12 art units • 0 of 18 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (6%) |
| §103 only | 6 (33%) |
| §112 only | 4 (22%) |
| Double-patenting + other | 2 (11%) |
| Multi-statute (no §101) | 5 (28%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLS, LAUREN QUINLAN | 1 | 46.6% | +60.6% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 0.0% | +0.0% |
| PIHONAK, SARAH | 1 | 61.1% | +42.9% |
| YOO, SUN JAE | 1 | 71.0% | +0.1% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.4% | +8.0% |
| JARRELL, NOBLE E | 1 | 80.9% | +9.6% |
| MCDOWELL, BRIAN E | 1 | 74.2% | +30.4% |
| FETTEROLF, BRANDON J | 1 | 51.4% | +17.1% |
| HABTE, KAHSAY | 1 | 85.1% | +7.3% |
| MOORE, SUSANNA | 1 | 67.9% | +31.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263702 | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES | HABTE, KAHSAY | 62d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17600107 | RTB-Based Permanent Magnet Material, Preparation Method thereof, and Application thereof | HILL, STEPHANI A | 42d overdue |
| 17785041 | NEODYMIUM-IRON-BORON MAGNET MATERIAL, RAW MATERIAL COMPOSITION PREPARATION METHOD THEREFOR AND USE THEREOF | O'KEEFE, SEAN P | 26d |
| 18684856 | CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | DEKARSKE, MADELINE MCGUIRE | — |
| 18294559 | COMPOSITION, FORMULATION, PREPARATION METHOD AND USE FOR GLUTATHIONE PRECURSOR | PIHONAK, SARAH | — |
| 18580154 | NOVEL PARP7 INHIBITOR AND USE THEREOF | YOO, SUN JAE | — |
| 18570661 | POTASSIUM CHANNEL MODULATOR, COMPOSITION AND APPLICATION | JARRELL, NOBLE E | — |
| 18248867 | SUBLINGUAL FILM DOSAGE OF RASAGILINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WISTNER, SARAH CLINKSCALES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550468 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | FETTEROLF, BRANDON J | 16d overdue |
| 18688377 | HALOGEN-SUBSTITUTED PYRIDAZINONE COMPOUND AND APPLICATION THEREOF | WELLS, LAUREN QUINLAN | — |
| 18294559 | COMPOSITION, FORMULATION, PREPARATION METHOD AND USE FOR GLUTATHIONE PRECURSOR | PIHONAK, SARAH | — |
| 18533232 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | MCDOWELL, BRIAN E | — |
| 18262724 | TRICYCLIC COMPOUNDS AND USE THEREOF | MOORE, SUSANNA | — |
| Art Unit | Apps |
|---|---|
| 1622 | 3 |
| 1624 | 3 |
| 1626 | 2 |
| 1734 | 2 |
| 1627 | 1 |
| 1621 | 1 |
| 1623 | 1 |
| 1699 | 1 |
| 1616 | 1 |
| 3799 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18688377 | HALOGEN-SUBSTITUTED PYRIDAZINONE COMPOUND AND APPLICATION THEREOF | Medshine Discovery Inc. | WELLS, LAUREN QUINLAN | 1622 | §103 | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18684856 | CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Best-Link Bioscience, LLC | DEKARSKE, MADELINE MCGUIRE | 1622 | §103 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18294559 | COMPOSITION, FORMULATION, PREPARATION METHOD AND USE FOR GLUTATHIONE PRECURSOR | Wuhan Grand Hoyo Co., Ltd. | PIHONAK, SARAH | 1627 | §101§103 | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18580154 | NOVEL PARP7 INHIBITOR AND USE THEREOF | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | YOO, SUN JAE | 1621 | §102§112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18571763 | IMIDAZOLE COMPOUND, AND INTERMEDIATE AND APPLICATION THEREOF | Xiaoqin Li | SHTERENGARTS, SAMANTHA L | 1623 | §112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18570661 | POTASSIUM CHANNEL MODULATOR, COMPOSITION AND APPLICATION | Neushen Therapeutics (Shanghai) Co., Ltd. | JARRELL, NOBLE E | 1699 | §102§103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18533232 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | Fujian Akeylink Biotechnology Co., Ltd. | MCDOWELL, BRIAN E | 1624 | §112 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18550468 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | Medshine Discovery Inc. | FETTEROLF, BRANDON J | 1626 | §112 | Non-Final OA | 16d overdue | Pending | Sep 14, 2023 |
| 18263702 | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES | Breakthrough Pharmaceuticals Inc. | HABTE, KAHSAY | 1624 | §103 | Non-Final OA | 62d | Pending | Jul 31, 2023 |
| 18262724 | TRICYCLIC COMPOUNDS AND USE THEREOF | Joyo (Chengdu) Pharmatech Co., Ltd. | MOORE, SUSANNA | 1624 | §103 | Final Rejection | — | Pending | Jul 24, 2023 |
| 18254186 | SALT OF PYRROLOPYRIMIDINE COMPOUND, CRYSTALLINE FORM THEREOF, AND APPLICATION THEREOF | Guangzhou Joyo Pharmatech Co., Ltd. | STOCKTON, LAURA LYNNE | 1626 | §102§112DP | Non-Final OA | — | Pending | May 24, 2023 |
| 18248867 | SUBLINGUAL FILM DOSAGE OF RASAGILINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Modern Pharmaceutical Engineering Research Center Co., Ltd. | WISTNER, SARAH CLINKSCALES | 1616 | §103§112 | Final Rejection | — | Pending | Apr 12, 2023 |
| 18042599 | AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §112 | Non-Final OA | — | Pending | Feb 23, 2023 |
| 18005963 | BIONIC TISSUE STENT, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Sinobioprint (Shanghai) Biotech Ltd. | PELLEGRINO, BRIAN E | 3799 | §103 | Final Rejection | — | Pending | Jan 18, 2023 |
| 17787283 | NEODYMIUM-IRON-BORON PERMANENT MAGNET MATERIAL, PREPARATION METHOD, AND APPLICATION | Fujian Golden Dragon Rare-Earth Co., Ltd. | YANG, JIE | 1734 | §103DP | Non-Final OA | 86d | Pending | Jun 17, 2022 |
| 17785041 | NEODYMIUM-IRON-BORON MAGNET MATERIAL, RAW MATERIAL COMPOSITION PREPARATION METHOD THEREFOR AND USE THEREOF | Fujian Golden Dragon Rare-Earth Co., Ltd. | O'KEEFE, SEAN P | 1738 | §103§112 | Non-Final OA | 26d | Pending | Jun 13, 2022 |
| 17635156 | R-T-B SERIES PERMANENT MAGNET MATERIAL, RAW MATERIAL COMPOSITION, PREPARATION METHOD AND APPLICATION | Fujian Golden Dragon Rare-Earth Co., Ltd. | WANG, NICHOLAS A | 1734 | §103 | Final Rejection | 45d overdue | Pending | Feb 14, 2022 |
| 17600107 | RTB-Based Permanent Magnet Material, Preparation Method thereof, and Application thereof | Fujian Golden Dragon Rare-Earth Co., Ltd. | HILL, STEPHANI A | 1735 | §103§112 | Final Rejection | 42d overdue | Pending | Sep 30, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial